Abstract
43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks. No response was observed. The most common side effect was myelotoxicity. Leukopenia occurred in 63% of the patients, thrombocytopenia in 67%, and anemia in 14%. Two episodes of acute dyspnea were observed which were thought to be pulmonary hypersensitivity reactions. This study does not suggest that mitomycin C is of value as second- or third-line treatment in metastatic breast cancer. It is likely that the drug could play a more important role in combination with other chemotherapeutic agents.
Original language | English |
---|---|
Pages (from-to) | 244-247 |
Number of pages | 4 |
Journal | Oncology |
Volume | 40 |
Issue number | 4 |
DOIs | |
Publication status | Published - 1983 |
Keywords
- Breast cancer
- Chemotherapy
- Mitomycin C
ASJC Scopus subject areas
- Cancer Research
- Oncology